Pharmaxis Ltd (ASX:PXS)'s Gary Phillips tells Proactive the third dose cohort in the phase 1c clinical trial for the drug PXS‐5505 as a potential new treatment for the bone marrow cancer myelofibrosis is already fully recruited and dosing of all patients is expected to commence at participating sites in Australian and South Korean hospitals shortly. He also discusses the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.
Pharmaxis updates on bone marrow cancer trial and talks potential of PXS-5505 in liver cancer
